European Union - English - EMA (European Medicines Agency)

baxalta innovations gmbh - vonicog alfa - von willebrand diseases - antihemorrhagics - veyvondi is indicated in adults (age 18 and older) with von willebrand disease (vwd), when desmopressin (ddavp) treatment alone is ineffective or not indicated for the- treatment of haemorrhage and surgical bleeding- prevention of surgical bleeding.veyvondi should not be used in the treatment of haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - vonicog alfa, quantity: 650 iu - injection, solvent for - excipient ingredients: water for injections - veyvondi is indicated in adults (age 18 and older) with von willebrand disease (vwd), when desmopressin (ddavp) treatment alone is ineffective or not indicated, for the,- treatment of haemorrhage and surgical bleeding,- prevention of surgical bleeding.,veyvondi should not be used in the treatment of haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - vonicog alfa, quantity: 1300 iu - injection, solvent for - excipient ingredients: water for injections - veyvondi is indicated in adults (age 18 and older) with von willebrand disease (vwd), when desmopressin (ddavp) treatment alone is ineffective or not indicated, for the,- treatment of haemorrhage and surgical bleeding,- prevention of surgical bleeding.,veyvondi should not be used in the treatment of haemophilia a.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

takeda pharmaceutical company limited. - vonicog alfa(genetical recombination) - white mass or powder injectable preparation

Canada - English - Health Canada

takeda canada inc - von willebrand factor (recombinant) - powder for solution - 650unit - von willebrand factor (recombinant) 650unit - hemostatics

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 250 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 3000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 2000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 1000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 500 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)